ANRO insider filings
Alto Neuroscience, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-05. Screen ANRO transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 1 filing by 1 insider — 134,886 shares, $3,567,247 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 110,830 shares @ $26.58 ($2,946,150) by Smith Nicholas Conrad, filed 2026-10-01.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Smith Nicholas Conrad — PRESIDENT AND CFO | 2 | — | 3 legs · 134,886 sh · $3,567,247 | 8 |
Recent insider filings — Alto Neuroscience, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-05 | 4 | Smith Nicholas Conrad — PRESIDENT AND CFO | Option exercise (M): 55,000 @ $2.32 · Option exercise (M): 55,000 (derivative) @ $0 | EDGAR |
| 2026-10-01 | 4 | Smith Nicholas Conrad — PRESIDENT AND CFO | Option exercise (M): 56,455 @ $2.35 · Option exercise (M): 54,375 @ $2.35 · Sale (S): 110,830 @ $26.58 · Option exercise (M): 24,056 @ $2.35 · Sale (S): 23,170 @ $25.78 · Sale (S): 886 @ $26.87 · +3 more | EDGAR |
| 2026-05-29 | 4 | Miller Andrew Craig — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Gift (G): 400,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Manji Husseini — Director | Grant/award (A): 10,958 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | York Gwill — Director | Grant/award (A): 10,958 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Cox Christopher Nixon — Director | Grant/award (A): 10,958 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Sanchez Ramiro — Director | Grant/award (A): 10,958 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Dreyfus Andrew — Director | Grant/award (A): 10,958 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER & CBO | Tax withholding (F): 2,806 @ $19.69 | EDGAR |
| 2026-03-03 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Tax withholding (F): 6,227 @ $19.69 | EDGAR |
| 2026-02-13 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER & CBO | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Savitz Adam — CHIEF MEDICAL OFFICER | Grant/award (A): 124,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Grant/award (A): 306,000 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Hanley Jr. Michael Conick — CHIEF OPERATING OFFICER | Grant/award (A): 131,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Manji Husseini — Director | Grant/award (A): 4,228 (derivative) @ $11.82 | EDGAR |
| 2026-01-06 | 4 | York Gwill — Director | Grant/award (A): 5,243 (derivative) @ $11.82 | EDGAR |
| 2026-01-06 | 4 | Cox Christopher Nixon — Director | Grant/award (A): 7,189 (derivative) @ $11.82 | EDGAR |
| 2026-01-06 | 4 | Sanchez Ramiro — Director | Grant/award (A): 3,806 (derivative) @ $11.82 | EDGAR |
| 2025-08-14 | 4 | Sanchez Ramiro — Director | Grant/award (A): 30,574 (derivative) @ $0 · Grant/award (A): 3,928 (derivative) @ $2.21 | EDGAR |
| 2025-07-08 | 4 | Savitz Adam — CHIEF MEDICAL OFFICER | Grant/award (A): 22,481 (derivative) · Disposition to issuer (D): 22,481 (derivative) · Grant/award (A): 33,008 (derivative) · Disposition to issuer (D): 33,008 (derivative) · Grant/award (A): 123,645 (derivative) · Disposition to issuer (D): 123,645 (derivative) · +4 more | EDGAR |
| 2025-07-08 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Grant/award (A): 34,620 (derivative) · Disposition to issuer (D): 34,620 (derivative) · Grant/award (A): 247,290 (derivative) · Disposition to issuer (D): 247,290 (derivative) · Grant/award (A): 223,000 (derivative) · Disposition to issuer (D): 223,000 (derivative) · +2 more | EDGAR |
| 2025-07-08 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER & CBO | Grant/award (A): 44,962 (derivative) · Disposition to issuer (D): 44,962 (derivative) · Grant/award (A): 33,833 (derivative) · Disposition to issuer (D): 33,833 (derivative) · Grant/award (A): 202,329 (derivative) · Disposition to issuer (D): 202,329 (derivative) · +4 more | EDGAR |
| 2025-07-08 | 4 | Hanley Jr. Michael Conick — CHIEF OPERATING OFFICER | Grant/award (A): 8,000 (derivative) · Disposition to issuer (D): 8,000 (derivative) · Grant/award (A): 188,000 (derivative) · Disposition to issuer (D): 188,000 (derivative) · Grant/award (A): 125,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) | EDGAR |
| 2025-05-15 | 4 | Manji Husseini — Director | Grant/award (A): 15,287 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Cox Christopher Nixon — Director | Grant/award (A): 15,287 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | York Gwill — Director | Grant/award (A): 15,287 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Dreyfus Andrew — Director | Grant/award (A): 15,287 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER & CBO | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Savitz Adam — CHIEF MEDICAL OFFICER | Grant/award (A): 76,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Hanley Jr. Michael Conick — CHIEF OPERATING OFFICER | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | York Gwill — Director | Grant/award (A): 19,558 (derivative) @ $3.17 | EDGAR |
| 2025-01-06 | 4 | Manji Husseini — Director | Grant/award (A): 14,195 (derivative) @ $3.17 | EDGAR |
| 2025-01-06 | 4 | Cox Christopher Nixon — Director | Grant/award (A): 25,236 (derivative) @ $3.17 | EDGAR |
| 2024-07-11 | 4 | Savitz Adam — CHIEF MEDICAL OFFICER | Purchase (P): 10,681 @ $12.53 · Purchase (P): 1,388 @ $13.15 · Purchase (P): 2,931 @ $13.22 | EDGAR |
| 2024-05-22 | 4 | Hanley Jr. Michael Conick — Chief Operating Officer | Grant/award (A): 188,000 (derivative) @ $0 | EDGAR |
| 2024-04-01 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER | Purchase (P): 1,600 @ $15.80 · Purchase (P): 4,550 @ $16.56 | EDGAR |
| 2024-03-12 | 4 | Radhakrishnan Maha — Director | Grant/award (A): 30,574 (derivative) @ $0 · Grant/award (A): 1,590 (derivative) @ $10.21 | EDGAR |
| 2024-03-06 | 4 | Apeiron Investment Group Ltd. Apeiron Presight Capital Fund II, L.P. Angermayer Christian | Conversion (C): 251,881 · Conversion (C): 674,658 · Conversion (C): 444,561 (derivative) · Conversion (C): 406,072 (derivative) · Conversion (C): 1,063,918 (derivative) · Conversion (C): 416,665 (derivative) | EDGAR |
| 2024-03-05 | 4 | Savitz Adam — CHIEF MEDICAL OFFICER | Grant/award (A): 73,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER | Grant/award (A): 19,153 @ $0 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Grant/award (A): 34,711 @ $0 · Grant/award (A): 223,000 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Alpha Wave Global, LP — 10% owner Alpha Wave Ventures GP, Ltd — 10% owner Lunate Holding RSC Ltd — 10% owner Chimera Investment LLC — 10% owner | Conversion (C): 1,962,995 · Conversion (C): 1,144,762 · Purchase (P): 600,000 @ $16 · Conversion (C): 1,962,995 (derivative) @ $0 · Conversion (C): 1,144,763 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | York Gwill — Director | Conversion (C): 23,917 · Conversion (C): 53,196 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | Smith Nicholas Conrad — CHIEF FINANCIAL OFFICER | Purchase (P): 1,563 @ $16 | EDGAR |
| 2024-02-07 | 4 | Cox Christopher Nixon — Director | Conversion (C): 588,898 · Conversion (C): 126,755 · Conversion (C): 1,250,000 (derivative) @ $0 · Conversion (C): 281,917 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | Savitz Adam — CHIEF MEDICAL OFFICER | Conversion (C): 7,851 · Purchase (P): 17,000 @ $16 · Conversion (C): 16,666 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | Etkin Amit — PRESIDENT AND CEO, Director | Conversion (C): 11,777 · Purchase (P): 3,125 @ $16 · Conversion (C): 25,000 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | Chen Po Yu (Jeff) — Director | Conversion (C): 39,259 · Conversion (C): 8,450 · Conversion (C): 83,333 (derivative) @ $0 · Conversion (C): 18,794 (derivative) @ $0 | EDGAR |
Recent 8-K events — Alto Neuroscience, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ANRO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →